KENNEWICK, Wash., Feb. 18, 2011 (GLOBE NEWSWIRE) -- James Katzaroff, Chairman and Chief Executive Officer of Advanced Medical Isotope Corporation (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, has been elected to the Board of Directors of the Washington Biotechnology & Biomedical Association (WBBA), based in Seattle.
The WBBA is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Its members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. The WBBA's Board of Directors is comprised of knowledgeable and experienced professionals actively overseeing the association's policies and strategy.
Chris E. Rivera, President of the WBBA, said, "Jim's achievements at the helm of Advanced Medical Isotope Corporation have cemented his reputation as a thought leader within the life sciences industry, and specifically within the biotechnology sector in the State of Washington. We are proud to have him serve on our Board, and look forward to harnessing his insights and expertise as we seek to enhance the prospects for life sciences companies in the Pacific Northwest region."
Mr. Katzaroff said, "It is a great honor to be elected to the WBBA Board. I look forward to joining a distinguished group of life sciences professionals who, like myself, are dedicated to the development of this industry within Washington State. Working together, we can go far to ensure enhanced opportunities for life science companies."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (OTCBB:ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC's goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, .
The Advanced Medical Isotope Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5139
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Our members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. Our mission is to translate innovation to realization: from breakthrough discoveries to better health solutions. WBBA will be hosting the 11th Annual Life Science Innovation Northwest Conference on March 2 and 3, 2011 at the Washington State Convention Center Seattle. Learn more about the WBBA and LSINW at .
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of Alternative Public Offering (APO) companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at .
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may", "will", "should", "plans", "expects", "anticipates", "continue", "estimates", "projects", "intends", and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT: Advanced Medical Isotope Corporation James C. Katzaroff (509) 736-4000 The Investor Relations Group 11 Stone St. 3rd Floor New York, NY 212-825-3210 IR: Adam Holdsworth/James Carbonara or PR: Laura Colontrelle/Janet Vasquez